Serum IFN-γ levels after in vivo depletion of NK cell or both NK cells and NK1+ T cells in the Shwartzman reactiona
| Mice . | Pretreatment . | Treatment . | Serum IFN-γ (pg/ml) . |
|---|---|---|---|
| B6 | None | None | None detected |
| None | IL-12 | 7593.1 ± 392.9b | |
| Anti-AGM1 Ab | IL-12 | 5343.3 ± 113.7† | |
| Anti-NK1 Ab | IL-12 | 1273.1 ± 209.2 | |
| β2m−/− | None | IL-12 | 2243.1 ± 206.4‡ |
| Mice . | Pretreatment . | Treatment . | Serum IFN-γ (pg/ml) . |
|---|---|---|---|
| B6 | None | None | None detected |
| None | IL-12 | 7593.1 ± 392.9b | |
| Anti-AGM1 Ab | IL-12 | 5343.3 ± 113.7† | |
| Anti-NK1 Ab | IL-12 | 1273.1 ± 209.2 | |
| β2m−/− | None | IL-12 | 2243.1 ± 206.4‡ |
Prior to treatment with nothing or 0.5 μg IL-12 (i.p.), mice were pretreated with nothing, anti-AGM1 Ab (50 μg/injection), or anti-NK1 Ab (200 μg/injection). Sera were collected 24 h after the IL-12 injection, and the IFN-γ levels were assayed. The data represented are mean ± SD of five mice in each group.
p < 0.01 vs anti-AGM1 Ab/IL-12-treated mice; †p < 0.01 vs anti-NK1 Ab/IL-12-treated mice; ‡p < 0.01 vs IL-12-treated B6 mice.